Hsu W H, Hopper D L
J Toxicol Environ Health. 1986;18(3):423-9. doi: 10.1080/15287398609530882.
Yohimbine was studied to examine its effectiveness in preventing central nervous system(CNS) depression and bradycardia induced by amitraz (N'-(2,4-dimethylphenyl)-N-[(2,4-dimethylphenyl-imino)-methyl]-N-methyl- methanimide). In control open-field activity experiments, the dogs showed high numbers of grid-line crossings in the first 5 min (exploratory phase), and subsequently low numbers of grid-line crossings (nonexploratory phase). An iv injection of amitraz (1 mg/kg) abolished both the exploratory and nonexploratory phases and caused bradycardia. Yohimbine alone caused a trend to increase the open-field activity in the nonexploratory phase. In addition, yohimbine prevented the bradycardia and suppression of open-field activity induced by amitraz. The results suggest that yohimbine has a potential to be used as an antidote for amitraz overdose.
研究了育亨宾预防由双甲脒(N'-(2,4-二甲基苯基)-N-[(2,4-二甲基苯基亚氨基)甲基]-N-甲基甲亚胺)引起的中枢神经系统(CNS)抑制和心动过缓的有效性。在对照旷场活动实验中,犬在最初5分钟(探索期)跨越网格线的次数较多,随后跨越网格线的次数较少(非探索期)。静脉注射双甲脒(1毫克/千克)消除了探索期和非探索期,并导致心动过缓。单独使用育亨宾有增加非探索期旷场活动的趋势。此外,育亨宾可预防双甲脒引起的心动过缓和旷场活动抑制。结果表明,育亨宾有潜力用作双甲脒过量的解毒剂。